Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study
Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, has transformed the treatment landscape through ECHELON trials, including ECHELON-1 in previously untreated advanced-stage classical Hodgkin lymphoma (cHL) [ 1 ], ECHELON-2 in peripheral T-cell lymphoma (PTCL) [ 2 ], and ECHELON-3 in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [ 3 ]. Based on these findings, BV-containing regimens have been included in the NCCN, ESMO, and CSCO guidelines as preferred treatment options for advanced cHL and CD30-positive PTCL [ 4 , 5 , 6 ].
Authors
- Huilai Zhang (ORCID: https://orcid.org/0000-0002-8558-3131)
- Bing Xu (ORCID: https://orcid.org/0000-0002-7271-4438)
- Jianli Wang (ORCID: https://orcid.org/0000-0002-7525-465X)
- Zheng Ge (ORCID: https://orcid.org/0000-0001-8028-1612)
- Chuanxu Liu (ORCID: https://orcid.org/0000-0002-3125-9547)
- Shi Ke-qian
- Weili Zhao (ORCID: https://orcid.org/0000-0002-6834-1616)
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Luqun Wang
- Shenmiao Yang (ORCID: https://orcid.org/0000-0001-7261-8449)
- Jing Hong-Mei
- Xiaobo Wang (ORCID: https://orcid.org/0000-0001-5057-5919)
- Hongyu Zhang (ORCID: https://orcid.org/0000-0003-0858-8681)
- Wei Zhang (ORCID: https://orcid.org/0000-0001-9489-5965)
- Fang Zhu (ORCID: https://orcid.org/0000-0002-2909-3736)
- Li Zengjun (ORCID: https://orcid.org/0000-0002-2881-3295)
- Ming-Ci Cai
- Guohui Cui
- Li-Ping Su
- Shaojie Wu
- Zhenqian Huang (ORCID: https://orcid.org/0009-0005-1677-9340)
- Ou Bai
- Fei Li
- Hong Liu
- Li-Hong Liu
- Hua-Qing Wang
- Wen-Xin Zhang
- Cai-Xia Li
- Wei Xu
- Yu-Fu Li
- Ling Qin
- Wen-Yang Huang
- Ying Lu
- Kai-Yang Ding
Institutions
- Ningbo University (CN)
- Hebei Medical University (CN)
- University of Science and Technology of China (CN)
- Shandong University (CN)
- Henan University of Science and Technology (CN)
- Shanghai Jiao Tong University (CN)
- Dalian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Ruijin Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Affiliated Hospital of Nantong University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- West China Hospital of Sichuan University (CN)
- First People's Hospital of Yunnan Province (CN)
- Fudan University Shanghai Cancer Center (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Shandong Tumor Hospital (CN)
- Second Affiliated Hospital of Dalian Medical University (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Zhongda Hospital Southeast University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Zhujiang Hospital (CN)
- Peking University People's Hospital (CN)
- First Hospital of Jilin University (CN)
- Peking University Shenzhen Hospital (CN)
- Wuhan Union Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Peking University Third Hospital (CN)
- Henan Cancer Hospital (CN)
- Shanghai Institute of Hematology (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Jiangsu Province Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Qilu Hospital of Shandong University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- State Key Laboratory of Experimental Hematology
- State Key Laboratory of Medical Genomics
- Huazhong University of Science and Technology (CN)
- Southern Medical University (CN)
- Southeast University (CN)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-09-30
- DOI
- https://doi.org/10.1038/s41408-026-01627-3
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00